Multiple NSAID-induced hits injure the small intestine: Underlying mechanisms and novel strategies

Toxicological Sciences

Volumn 131, Issue 2, 2013, Pages 654-667

  Boelsterli, Urs A ^a   Redinbo, Matthew R ^b   Saitta, Kyle S ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

glucuronidase; Enteropathy; Glucuronides; Intestinal microbiome; NSAIDs

Indexed keywords

AGLYCONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BACTERIAL TOXIN; BETA GLUCURONIDASE; CARBOXYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHILIN D; CYTOCHROME P450; DICLOFENAC; DRUG METABOLITE; GLYCOSIDASE INHIBITOR; HIGH MOBILITY GROUP B1 PROTEIN; INDOMETACIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYLPROPIONIC ACID DERIVATIVE; PHOSPHATIDYLCHOLINE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; UNINDEXED DRUG;

ACTINOBACTERIA; ARTICLE; BIFIDOBACTERIACEAE; CELL DEATH; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; HUMAN; INTESTINE CELL; INTESTINE INJURY; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PH; POSTOPERATIVE INFLAMMATION; PROTEIN EXPRESSION; SACCHAROMYCES CEREVISIAE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; IMMUNITY, INNATE; INTESTINE, SMALL;

EID: 84873854068     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs310     Document Type: Article

References (115)

1. Adler, D. H., Phillips, J. A., 3rd, Cogan, J. D., Iverson, T. M., Schnetz-Boutaud, N., Stein, J. A., Brenner, D. A., Milne, G. L., Morrow, J. D., Boutaud, O., et al. (2009). The enteropathy of prostaglandin deficiency. J. Gastroenterol. 44(Suppl. 19), 1-7.
2. Ahmad, S., Hughes, M. A., Lane, K. T., Redinbo, M. R., Yeh, L. A., and Scott, J. E. (2011). A high throughput assay for discovery of bacterial β-glucuronidase inhibitors. Curr. Chem. Genomics 5, 13-20.
3. Al-Nasser, I. A. (2000). Ibuprofen-induced liver mitochondrial permeability transition. Toxicol. Lett. 111, 213-218.
4. Allison, M. C., Howatson, A. G., Torrance, C. J., Lee, F. D., and Russell, R. I. (1992). Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 327, 749-754.
5. Anthony, A., Dhillon, A. P., Nygard, G., Hudson, M., Piasecki, C., Strong, P., Trevethick, M. A., Clayton, N. M., Jordan, C. C., and Pounder, R. E. (1993). Early histological features of small intestinal injury induced by indomethacin. Aliment. Pharmacol. Ther. 7, 29-39.
6. Atchison, C. R., West, A. B., Balakumaran, A., Hargus, S. J., Pohl, L. R., Daiker, D. H., Aronson, J. F., Hoffmann, W. E., Shipp, B. K., and Treinen-Moslen, M. (2000). Drug enterocyte adducts: Possible causal factor for diclofenac enteropathy in rats. Gastroenterology 119, 1537-1547.
7. Baines, C. P. (2009). The molecular composition of the mitochondrial permeability transition pore. J. Mol. Cell. Cardiol. 46, 850-857.
8. Beck, P. L., Xavier, R., Lu, N., Nanda, N. N., Dinauer, M., Podolsky, D. K., and Seed, B. (2000). Mechanisms of NSAID-induced gastrointestinal injury defined using mutant mice. Gastroenterology 119, 699-705.
9. Bertrand, V., Guimbaud, R., Tulliez, M., Mauprivez, C., Sogni, P., Couturier, D., Giroud, J. P., Chaussade, S., and Chauvelot-Moachon, L. (1998). Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br. J. Pharmacol. 124, 1385-1394.
10. Bjarnason, I., Hayllar, J., MacPherson, A. J., and Russell, A. S. (1993). Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104, 1832-1847.
11. Björnsson, E., Westgaard, G., and Bjarnason, I. (2008). Severe injury to the small bowel associated with a short course of diclofenac. Scand. J. Gastroenterol. 43, 759-760.
12. Boelsterli, U. A. (2003). Disease-related determinants of susceptibility to druginduced idiosyncratic hepatotoxicity. Curr. Opin. Drug Discov. Devel. 6, 81-91.
13. Boelsterli, U. A., and Ramirez-Alcantara, V. (2011). NSAID acyl glucuronides and enteropathy. Curr. Drug Metab. 12, 245-252.
14. Brunelle, F. M., and Verbeeck, R. K. (1993). Glucuronidation of diflunisal by rat liver microsomes. Effect of microsomal beta-glucuronidase activity. Biochem. Pharmacol. 46, 1953-1958.
15. Bruyère, A., Declevès, X., Bouzom, F., Proust, L., Martinet, M., Walther, B., and Parmentier, Y. (2009). Development of an optimized procedure for the preparation of rat intestinal microsomes: Comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica. 39, 22-32.
16. Burnett, B. P., and Levy, R. M. (2012). 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity. Adv. Ther. 29, 79-98.
17. Cury, D. H., Costa, J. E., Irika, K., Mijji, L., Garcez, A., Buchiguel, C., Silva, I., and Sipahi, A. (2008). Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. Dig. Dis. Sci. 53, 2516-2520.
18. Dabek, M., McCrae, S. I., Stevens, V. J., Duncan, S. H., and Louis, P. (2008). Distribution of beta-glucosidase and beta-glucuronidase activity and of betaglucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 66, 487-495.
19. Daniell, H. W. (2012). NSAID-PPI enteropathy in humans. Gastroenterology 142, e20.
20. Davies, N. M. (1995). Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis. Colon Rectum 38, 1311-1321.
21. Davies, N. M., Saleh, J. Y., and Skjodt, N. M. (2000). Detection and prevention of NSAID-induced enteropathy. J. Pharm. Pharm. Sci. 3, 137-155.
22. DeSesso, J. M., and Jacobson, C. F. (2001). Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 39, 209-228.
23. Dial, E. J., Darling, R. L., and Lichtenberger, L. M. (2008). Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury. J. Gastroenterol. Hepatol. 23(8 Pt 2), e384-e389.
24. Dickinson, R. G. (2011). Iso-glucuronides. Curr. Drug Metab. 12, 222-228.
25. Duggan, D. E., Hooke, K. F., Noll, R. M., and Kwan, K. C. (1975). Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem. Pharmacol. 24, 1749-1754.
26. Evans, D. F., Pye, G., Bramley, R., Clark, A. G., Dyson, T. J., and Hardcastle, J. D. (1988). Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29, 1035-1041.
27. Fortun, P. J., and Hawkey, C. J. (2007). Nonsteroidal antiinflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 23, 134-141.
28. Fujimori, S., Gudis, K., Takahashi, Y., Seo, T., Yamada, Y., Ehara, A., Kobayashi, T., Mitsui, K., Yonezawa, M., Tanaka, S., et al. (2010). Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur. J. Clin. Invest. 40, 504-510.
29. Fujimori, S., Seo, T., Gudis, K., Ehara, A., Kobayashi, T., Mitsui, K., Yonezawa, M., Tanaka, S., Tatsuguchi, A., and Sakamoto, C. (2009). Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: A pilot randomized controlled trial evaluated by capsule endoscopy. Gastrointest. Endosc. 69, 1339-1346.
30. Fujimori, S., Takahashi, Y., Gudis, K., Seo, T., Ehara, A., Kobayashi, T., Mitsui, K., Yonezawa, M., Tanaka, S., Tatsuguchi, A., et al. (2011). Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: A double-blind, randomized, controlled trial evaluated by capsule endoscopy. J. Gastroenterol. 46, 57-64.
31. Fukumoto, K., Naito, Y., Takagi, T., Yamada, S., Horie, R., Inoue, K., Harusato, A., Hirata, I., Omatsu, T., Mizushima, K., et al. (2011). Role of tumor necrosis factor-α in the pathogenesis of indomethacin-induced small intestinal injury in mice. Int. J. Mol. Med. 27, 353-359.
32. Halestrap, A. P. (2009). What is the mitochondrial permeability transition pore? J. Mol. Cell. Cardiol. 46, 821-831.
33. Harusato, A., Naito, Y., Takagi, T., Uchiyama, K., Mizushima, K., Hirai, Y., Yamada, S., Tuji, T., Yoriki, H., Horie, R., et al. (2011). Suppression of indomethacin-induced apoptosis in the small intestine due to Bach1 deficiency. Free Radic. Res. 45, 717-727.
34. Hawksworth, G., Drasar, B. S., and Hill, M. J. (1971). Intestinal bacteria and the hydrolysis of glycosidic bonds. J. Med. Microbiol. 4, 451-459.
35. Hobbs, S. S., Goettel, J. A., Liang, D., Yan, F., Edelblum, K. L., Frey, M. R., Mullane, M. T., and Polk, D. B. (2011). TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G220-G229.
36. Hotz-Behofsits, C., Simpson, R. J., Walley, M., and Bjarnason, I. T. (2010). Role of COX-2 in nonsteroidal anti-inflammatory drug enteropathy in rodents. Scand. J. Gastroenterol. 45, 822-827.
37. Kaminsky, L. S., and Zhang, Q. Y. (2003). The small intestine as a xenobioticmetabolizing organ. Drug Metab. Dispos. 31, 1520-1525.
38. Kato, S., Ito, Y., Nishio, H., Aoi, Y., Amagase, K., and Takeuchi, K. (2007). Increased susceptibility of small intestine to NSAID-provoked ulceration in rats with adjuvant-induced arthritis: Involvement of enhanced expression of TLR4. Life Sci. 81, 1309-1316.
39. Kent, T. H., Cardelli, R. M., and Stamler, F. W. (1969). Small intestinal ulcers and intestinal flora in rats given indomethacin. Am. J. Pathol. 54, 237-249.
40. King, C., Tang, W., Ngui, J., Tephly, T., and Braun, M. (2001). Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci. 61, 49-53.
41. Komura, H., and Iwaki, M. (2011). In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: Species differences. Drug Metab. Rev. 43, 476-498.
42. Ku, E. C., Lee, W., Kothari, H. V., and Scholer, D. W. (1986). Effect of diclofenac sodium on the arachidonic acid cascade. Am. J. Med. 80(4B), 18-23.
43. Lagas, J. S., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., and Schinkel, A. H. (2010). Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol. Pharmacol. 77, 687-694.
44. Langenbach, R., Loftin, C., Lee, C., and Tiano, H. (1999). Cyclooxygenase knockout mice: Models for elucidating isoform-specific functions. Biochem. Pharmacol. 58, 1237-1246.
45. Lerche, C. M., Philipsen, P. A., Poulsen, T., and Wulf, H. C. (2011). High death rate in mice treated topically with diclofenac. Exp. Dermatol. 20, 336-338.
46. Lichtenberger, L. M., Zhou, Y., Jayaraman, V., Doyen, J. R., O'Neil, R. G., Dial, E. J., Volk, D. E., Gorenstein, D. G., Boggara, M. B., and Krishnamoorti, R. (2012). Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: Characterization of interaction of NSAIDs with phosphatidylcholine. Biochim. Biophys. Acta 1821, 994-1002.
47. LoGuidice, A., Ramirez-Alcantara, V., Proli, A., Gavillet, B., and Boelsterli, U. A. (2010). Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice. Toxicol. Sci. 118, 276-285.
48. LoGuidice, A., Wallace, B. D., Bendel, L., Redinbo, M. R., and Boelsterli, U. A. (2012). Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J. Pharmacol. Exp. Ther. 341, 447-454.
49. Maehata, Y., Esaki, M., Morishita, T., Kochi, S., Endo, S., Shikata, K., Kobayashi, H., and Matsumoto, T. (2012). Small bowel injury induced by selective cyclooxygenase-2 inhibitors: A prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. J. Gastroenterol. 47, 387-393.
50. Mahmud, T., Scott, D. L., and Bjarnason, I. (1996). A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann. Rheum. Dis. 55, 211-213.
51. Maiden, L. (2009). Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J. Gastroenterol. 44(Suppl. 19), 64-71.
52. Maiden, L., Thjodleifsson, B., Seigal, A., Bjarnason, I. I., Scott, D., Birgisson, S., and Bjarnason, I. (2007). Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: A cross-sectional capsule enteroscopy study. Clin. Gastroenterol. Hepatol. 5, 1040-1045.
53. Maier, T. J., Tausch, L., Hoernig, M., Coste, O., Schmidt, R., Angioni, C., Metzner, J., Groesch, S., Pergola, C., Steinhilber, D., et al. (2008). Celecoxib inhibits 5-lipoxygenase. Biochem. Pharmacol. 76, 862-872.
54. Masubuchi, Y., Nakayama, S., and Horie, T. (2002). Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35, 544-551.
55. Masubuchi, Y., Yamada, S., and Horie, T. (2000). Possible mechanism of hepatocyte injury induced by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 292, 982-987.
56. McConnell, E. L., Basit, A. W., and Murdan, S. (2008). Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J. Pharm. Pharmacol. 60, 63-70.
57. McCormack, K., and Brune, K. (1987). Classical absorption theory and the development of gastric mucosal damage associated with the non-steroidal anti-inflammatory drugs. Arch. Toxicol. 60, 261-269.
58. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A., Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397.
59. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., and Janeway, C. A., Jr. (1998). MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2, 253-258.
60. Mohri, K., Okada, K., and Benet, L. Z. (1998). Stereoselective metabolism of benoxaprofen in rats. Biliary excretion of benoxaprofen taurine conjugate and glucuronide. Drug Metab. Dispos. 26, 332-337.
61. Montrose, D. C., Kadaveru, K., Ilsley, J. N., Root, S. H., Rajan, T. V., Ramesh, M., Nichols, F. C., Liang, B. T., Sonin, D., Hand, A. R., et al. (2010). cPLA2 is protective against COX inhibitor-induced intestinal damage. Toxicol. Sci. 117, 122-132.
62. Nadanaciva, S., Bernal, A., Aggeler, R., Capaldi, R., and Will, Y. (2007). Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol. In Vitro 21, 902-911.
63. Nadatani, Y., Watanabe, T., Tanigawa, T., Machida, H., Okazaki, H., Yamagami, H., Watanabe, K., Tominaga, K., Fujiwara, Y., and Arakawa, T. (2012). High mobility group box 1 promotes small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like receptor 4. Am. J. Pathol. 181, 98-110.
64. Nakanishi, Y., Matsushita, A., Matsuno, K., Iwasaki, K., Utoh, M., Nakamura, C., and Uno, Y. (2010). Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab. Pharmacokinet. 25, 290-297.
65. Nakanishi, Y., Matsushita, A., Matsuno, K., Iwasaki, K., Utoh, M., Nakamura, C., and Uno, Y. (2011). Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys. Drug Metab. Pharmacokinet. 26, 288-294.
66. Nazli, A., Yang, P. C., Jury, J., Howe, K., Watson, J. L., Söderholm, J. D., Sherman, P. M., Perdue, M. H., and McKay, D. M. (2004). Epithelia under metabolic stress perceive commensal bacteria as a threat. Am. J. Pathol. 164, 947-957.
67. Ohyama, K., Shiokawa, A., Ito, K., Masuyama, R., Ichibangase, T., Kishikawa, N., Imai, K., and Kuroda, N. (2012). Toxicoproteomic analysis of a mouse model of nonsteroidal anti-inflammatory drug-induced gastric ulcers. Biochem. Biophys. Res. Commun. 420, 210-215.
68. Park, S. C., Chun, H. J., Kang, C. D., and Sul, D. (2011). Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J. Gastroenterol. 17, 4647-4653.
69. Peris-Ribera, J. E., Torres-Molina, F., Garcia-Carbonell, M. C., Aristorena, J. C., and Pla-Delfina, J. M. (1991). Pharmacokinetics and bioavailability of diclofenac in the rat. J. Pharmacokinet. Biopharm. 19, 647-665.
70. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998). Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 282, 2085-2088.
71. Quarato, G., D'Aprile, A., Gavillet, B., Vuagniaux, G., Moradpour, D., Capitanio, N., and Piccoli, C. (2012). The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction. Hepatology 55, 1333-1343.
72. Rainsford, K. D., and Bjarnason, I. (2012). NSAIDs: Take with food or after fasting? J. Pharm. Pharmacol. 64, 465-469.
73. Ramirez-Alcantara, V., LoGuidice, A., and Boelsterli, U. A. (2009). Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G990-G998.
74. Reuter, B. K., Davies, N. M., and Wallace, J. L. (1997). Nonsteroidal antiinflammatory drug enteropathy in rats: Role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112, 109-117.
75. Robert, A., and Asano, T. (1977). Resistance of germfree rats to indomethacininduced intestinal lesions. Prostaglandins 14, 333-341.
76. Sandoval-Acuña, C., Lopez-Alarcón, C., Aliaga, M. E., and Speisky, H. (2012). Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chem. Biol. Interact. 199, 18-28.
77. Sapirstein, A., and Bonventre, J. V. (2000). Specific physiological roles of cytosolic phospholipase A(2) as defined by gene knockouts. Biochim. Biophys. Acta 1488, 139-148.
78. Sarda, S., Page, C., Pickup, K., Schulz-Utermoehl, T., and Wilson, I. (2012). Diclofenac metabolism in the mouse: Novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica. 42, 179-194.
79. Satoh, H., Amagase, K., and Takeuchi, K. (2012). Exacerbation of nonsteroidal anti-inflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: The role of intestinal motility. J. Pharmacol. Exp. Ther. 343, 270-277.
80. Satoh, H., and Takeuchi, K. (2012). Role of food and enterobacteria in the formation and prevention of small intestinal damage induced by NSAIDs. In Cell/ Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment (L. P. Filaretova and K. Takeuchi, Eds.), pp. 52-60. Karger, Basel, Switzerland.
81. Scarpignato, C., and Hunt, R. H. (2010). Nonsteroidal antiinflammatory drugrelated injury to the gastrointestinal tract: Clinical picture, pathogenesis, and prevention. Gastroenterol. Clin. North Am. 39, 433-464.
82. Seitz, S., and Boelsterli, U. A. (1998). Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 115, 1476-1482.
83. Sidhu, R., Brunt, L. K., Morley, S. R., Sanders, D. S., and McAlindon, M. E. (2010). Undisclosed use of nonsteroidal anti-inflammatory drugs may underlie small-bowel injury observed by capsule endoscopy. Clin. Gastroenterol. Hepatol. 8, 992-995.
84. Sigthorsson, G., Simpson, R. J., Walley, M., Anthony, A., Foster, R., Hotz-Behoftsitz, C., Palizban, A., Pombo, J., Watts, J., Morham, S. G., et al. (2002). COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal antiinflammatory drug enteropathy in mice. Gastroenterology 122, 1913-1923.
85. Somasundaram, S., Rafi, S., Hayllar, J., Sigthorsson, G., Jacob, M., Price, A. B., Macpherson, A., Mahmod, T., Scott, D., Wrigglesworth, J. M., et al. (1997). Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 41, 344-353.
86. Somasundaram, S., Sigthorsson, G., Simpson, R. J., Watts, J., Jacob, M., Tavares, I. A., Rafi, S., Roseth, A., Foster, R., Price, A. B., et al. (2000). Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAIDenteropathy in the rat. Aliment. Pharmacol. Ther. 14, 639-650.
87. Stadnyk, A. W., Dollard, C., Issekutz, T. B., and Issekutz, A. C. (2002). Neutrophil migration into indomethacin induced rat small intestinal injury is CD11a/CD18 and CD11b/CD18 co-dependent. Gut 50, 629-635.
88. Takeuchi, K., Kato, S., and Amagase, K. (2010a). Prostaglandin EP receptors involved in modulating gastrointestinal mucosal integrity. J. Pharmacol. Sci. 114, 248-261.
89. Takeuchi, K., Tanaka, A., Kato, S., Amagase, K., and Satoh, H. (2010b). Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin. Chim. Acta 411, 459-466.
90. Takeuchi, K., Tanigami, M., Amagase, K., Ochi, A., Okuda, S., and Hatazawa, R. (2010c). Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors. J. Gastroenterol. Hepatol. 25(Suppl. 1), S67-S74.
91. Tanaka, A., Hase, S., Miyazawa, T., Ohno, R., and Takeuchi, K. (2002a). Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal antiinflammatory drug-induced intestinal damage in rats: Relation to various pathogenic events. J. Pharmacol. Exp. Ther. 303, 1248-1254.
92. Tanaka, A., Hase, S., Miyazawa, T., and Takeuchi, K. (2002b). Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: A key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J. Pharmacol. Exp. Ther. 300, 754-761.
93. Tanaka, K., Tomisato, W., Hoshino, T., Ishihara, T., Namba, T., Aburaya, M., Katsu, T., Suzuki, K., Tsutsumi, S., and Mizushima, T. (2005). Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J. Biol. Chem. 280, 31059-31067.
94. Tay, V. K., Wang, A. S., Leow, K. Y., Ong, M. M., Wong, K. P., and Boelsterli, U. A. (2005). Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic. Biol. Med. 39, 949-959.
95. Tremaroli, V., and Bäckhed, F. (2012). Functional interactions between the gut microbiota and host metabolism. Nature 489, 242-249.
96. Tsutsumi, S., Gotoh, T., Tomisato, W., Mima, S., Hoshino, T., Hwang, H. J., Takenaka, H., Tsuchiya, T., Mori, M., and Mizushima, T. (2004). Endoplasmic reticulum stress response is involved in nonsteroidal antiinflammatory drug-induced apoptosis. Cell Death Differ. 11, 1009-1016.
97. Uejima, M., Kinouchi, T., Kataoka, K., Hiraoka, I., and Ohnishi, Y. (1996). Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol. Immunol. 40, 553-560.
98. Uyemura, S. A., Santos, A. C., Mingatto, F. E., Jordani, M. C., and Curti, C. (1997). Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch. Biochem. Biophys. 342, 231-235.
99. Vaishnava, S., Yamamoto, M., Severson, K. M., Ruhn, K. A., Yu, X., Koren, O., Ley, R., Wakeland, E. K., and Hooper, L. V. (2011). The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334, 255-258.
100. van Leeuwen, J. S., Orij, R., Luttik, M. A., Smits, G. J., Vermeulen, N. P., and Vos, J. C. (2011). Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiology (Reading, Engl.) 157(Pt 3), 685-694.
101. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231, 232-235.
102. Vogel, S. N., Wax, J. S., Perera, P. Y., Padlan, C., Potter, M., and Mock, B. A. (1994). Construction of a BALB/c congenic mouse, C.C3H-Lpsd, that expresses the Lpsd allele: Analysis of chromosome 4 markers surrounding the Lps gene. Infect. Immun. 62, 4454-4459.
103. Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L. A., Mani, S., et al. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831-835.
104. Wallace, J. L. (2012). NSAID gastropathy and enteropathy: Distinct pathogenesis likely necessitates distinct prevention strategies. Br. J. Pharmacol. 165, 67-74.
105. Wallace, J. L., McKnight, W., Reuter, B. K., and Vergnolle, N. (2000). NSAIDinduced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119, 706-714.
106. Wallace, J. L., Syer, S., Denou, E., de Palma, G., Vong, L., McKnight, W., Jury, J., Bolla, M., Bercik, P., Collins, S. M., et al. (2011). Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 141, 1314-22, 1322.e1.
107. Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999). HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-251.
108. Watanabe, T., Higuchi, K., Kobata, A., Nishio, H., Tanigawa, T., Shiba, M., Tominaga, K., Fujiwara, Y., Oshitani, N., Asahara, T., et al. (2008). Nonsteroidal anti-inflammatory drug-induced small intestinal damage is Tolllike receptor 4 dependent. Gut 57, 181-187.
109. Watanabe, T., Tanigawa, T., Nadatani, Y., Otani, K., Machida, H., Okazaki, H., Yamagami, H., Watanabe, K., Tominaga, K., Fujiwara, Y., et al. (2011). Mitochondrial disorders in NSAIDs-induced small bowel injury. J. Clin. Biochem. Nutr. 48, 117-121.
110. Wax, J., Clinger, W. A., Varner, P., Bass, P., and Winder, C. V. (1970). Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 58, 772-780.
111. Whittle, B. J. (2004). Mechanisms underlying intestinal injury induced by antiinflammatory COX inhibitors. Eur. J. Pharmacol. 500, 427-439.
112. Wolfe, M. M., Lichtenstein, D. R., and Singh, G. (1999). Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340, 1888-1899.
113. Wright, M. R., Davies, N. M., and Jamali, F. (1997). Toxicokinetics of indomethacin-induced intestinal permeability in the rat. Pharmacol. Res. 35, 499-504.
114. Yamada, S., Naito, Y., Takagi, T., Mizushima, K., Hirai, Y., Horie, R., Fukumoto, K., Inoue, K., Harusato, A., Yoshida, N., et al. (2011). Reduced small-intestinal injury induced by indomethacin in interleukin-17A-deficient mice. J. Gastroenterol. Hepatol. 26, 398-404.
115. Zhu, Y., and Zhang, Q. Y. (2012). Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine. J. Pharmacol. Exp. Ther. 343, 362-370.